Trusted Biotechnology Investments Experts

AI meets biotech — straight from Zug, Switzerland Get the latest AI news, learn must-know AI tools, and keep up with Biotech news in just 5 minutes a week. Join our readers growing their careers with the AIxBiotech newsletter. Founded by executives who have led global biotech and tech teams, AIxBiotech is on a mission to make AI practical for themodern biotech office. In just a few months, we’ve attracted a fast-growing audience of biotech professionals and innovation leaders — from early-stage founders to Fortune 500 executives. Our readers span Europe and North America, with a strong base in the U.S. and Switzerland. We’re building organically, one engaged reader at a time — with the ambition to reach 500K professionals within our first year.

Authentic technology recruitment leader with expertise in executive talent acquisition and building high performance recruitment teams, primarily within the tech/digital/creative disciplines.

Founder of IngredientMD, a supplement intelligence platform powdered by most clinical data available. What's important, we communicate in language humans will understand instead. It all starts from individual ingredients instead of product name, claims, and anything else. Product is what's inside instead of what perception is being made. In our analysis of 500+ supplement products, we found 42% had at least one key ingredient below clinically studied doses. I focus on bringing evidence-based analysis to consumer supplement decisions.

Jason White is the CEO and majority owner of LEC Partners, a Cambridge, MA-based advisory firm that has helped clients navigate the bioeconomy for over 30 years. He works with investors, developers, and operators to evaluate technologies, structure projects, and reduce technical and commercial risk in areas such as renewable fuels, biomaterials, and low-carbon feedstocks. Jason’s background spans four continents and multiple industries, including fintech, medtech, and renewable energy. Before leading LEC Partners, he ran a fintech and consulting firm in Shenzhen, advised the founder of a medical device startup in Switzerland, and managed C-suite relationships with major retailers, banks, IT firms, and private equity investors. This mix of operating, deal-making, and cross-border experience gives Jason a practical perspective on how emerging technologies move from concept to bankable projects. Journalists often turn to him for clear explanations of complex topics such as project development risk, bioeconomy policy impacts, and how investors are underwriting new technologies in real deals. Jason is based in the Greater Boston area with his family, where he is raising two sons, coaching youth sports, and staying closely engaged with the next generation of problem-solvers.

With a PhD in molecular genetics and as a specialist in data science, Céline Chantry-Darmon has over twenty years of experience in biomedical research and complex data analysis. As Scientific Director at Tekkare, she works on developing trustworthy artificial intelligence for healthcare. She is also committed to promoting inclusive and responsible artificial intelligence, and to advancing women in science and technology.

Dr. Robert Abraham is a regenerative medicine consultant and healthcare strategy advisor with more than a decade of experience operating multi-location healthcare practices. He earned his Bachelor of Science in Health Sciences and Biology from the University of Central Florida before pursuing advanced training in clinical operations and regenerative-focused program development. Based in Florida, Dr. Abraham has worked with healthcare organizations throughout the Orlando region and nationwide, advising clinics on structured implementation, operational systems design, revenue forecasting, and compliance-conscious growth within regenerative medicine and wound care services. In addition to his consulting work, he serves as Chief Executive Officer of Cross Biotech, a biologics distribution company supporting providers in aligning product access with disciplined operational frameworks. His work emphasizes infrastructure-driven expansion, leadership accountability, and sustainable healthcare systems.

Achal Shah is VP of Strategic Development at Monetrey Mushrooms, a food and biotech company in the agriculture space, and a published contributor to AgFunderNews. With over 10 years of experience at the intersection of food, agriculture, and innovation, Achal has advised leading agribusinesses at McKinsey & Company and served as Global Strategy Lead and Chief of Staff to the CEO at RiceTec, a global seed company operating across the U.S., India, and Brazil. He has led strategies spanning seed genetics, sustainable farming, agri-biotech commercialization, digital transformation, and M&A — and spearheaded a multi-continent initiative to drive hybrid rice adoption that reduced methane emissions, cut water consumption, and improved profitability for smallholder farmers. Achal holds an MBA from the Kellogg School of Management and a Master’s in Design Innovation from Northwestern University. He is available to comment on agribusiness strategy, agricultural biotech, food system innovation, sustainable farming, and emerging trends shaping the global agriculture industry.

Dr. Akshaya Srikanth Bhagavathula is an Associate Professor of Epidemiology at North Dakota State University, internationally recognized for his pioneering work at the intersection of digital epidemiology, pharmacovigilance, and artificial intelligence. His research harnesses advanced statistical modeling and AI to track and predict health behaviors, medication safety, and disease patterns in real time—bridging traditional epidemiology with next-generation digital health analytics. Dr. Bhagavathula has published more than 250 peer-reviewed articles in leading journals, including Annals of Epidemiology, JAMA Network Open, and Lancet Digital Health. His work has been widely cited and featured in major media outlets such as The New York Times, where he discussed the real-world safety of GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy, Mounjaro). Recognized among the Stanford–Elsevier Top 2% of Scientists (2019–2024) and elected as a Fellow of the American College of Epidemiology, Dr. Bhagavathula is known for translating complex data into actionable insights that shape public health policy and clinical practice. His ongoing projects include NIH- and NSF-aligned initiatives on AI-powered overdose forecasting, digital twins for public health, and real-world drug safety surveillance using explainable machine learning. With a decade of experience spanning more than two dozen countries and collaborations with organizations such as WHO, USAID, and UNICEF, Dr. Bhagavathula brings a global, data-driven, and human-centered approach to solving modern health crises.

I’m an entrepreneur working at the intersection of AI, product execution, and healthcare access. Over the last decade I’ve built and led teams that turn new technology into practical tools for real businesses. I co-founded BotsCrew in 2016, grew it into a global AI services company, and later joined the CourtAvenue collective, where we help large enterprises adopt generative AI with speed and precision. I also founded AllClinicalTrials.com and Curify, two platforms focused on making it easier for patients to find and enroll in legitimate clinical trials. That work started from a personal experience trying to find treatment options for a family member, and it pushed me toward building products that remove friction from complex systems. My background is in applied mathematics and AI, but most of my learning came from building things fast, talking to customers, and fixing what didn’t work. I’m especially interested in how generative AI will reshape operations, customer experience, and decision-making in large organizations. I try to share what I learn - both the wins and the mistakes - so others can move faster.

Vijay Amin is the Founder & CEO of VertiComply, an AI-powered no-code platform that generates owned, exportable, production-ready healthcare app code with 15+ compliance frameworks enforced at the code level — including HIPAA, GDPR, SOC 2, FDA 21 CFR Part 11, EU AI Act, ISO 27001, HITRUST, ABDM, and DPDP. With 21 years of enterprise IT experience across healthcare, cloud infrastructure, and AI, Vijay has spent his career at the intersection of highly regulated industries and emerging technology. He founded VertiComply after seeing the same pattern repeat across digital health teams: AI-generated code that looked compliant but failed the moment a real audit, security review, or partner onboarding arrived. The platform is built for healthcare startups, digital health teams, and non-technical founders who need to ship fast without compromising on ownership, security, or regulatory rigor. Vijay's areas of expertise include: 1. Healthcare data privacy and HIPAA compliance 2. AI-generated code risk in regulated industries 3. The EU AI Act and its impact on US healthcare and digital health companies 4. Multi-framework compliance overlap (HIPAA + GDPR + FDA 21 CFR Part 11 + SOC 2) 5. No-code and low-code platforms for healthcare app development 6. Cloud security and infrastructure for HIPAA-regulated workloads 7. Compliance challenges for early-stage healthcare and digital health startups 8. India's digital health stack (ABDM, DPDP Act) and cross-border compliance He is available for expert quotes, background commentary, and contributed articles on healthcare IT, AI compliance, cybersecurity, digital health, and the evolving regulatory landscape for AI in regulated industries. Vijay can also connect journalists with healthcare CTOs, compliance officers, and digital health founders within VertiComply's network for additional sourcing. Based in Ahmedabad, India, Vijay leads VertiComply alongside co-founder and CTO Garvita Solanki, who brings 15 years of engineering experience.

Andrea is an entrepreneur & global expert in 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲, 𝐠𝐫𝐞𝐞𝐧 𝐭𝐞𝐜𝐡 𝐚𝐧𝐝 𝐞𝐧𝐞𝐫𝐠𝐲 𝐭𝐫𝐚𝐧𝐬𝐢𝐭𝐢𝐨𝐧. He is the founder & "Chief Earth Officer" (i.e. a CEO on a mission for our planet) at 𝐢𝐥𝐥𝐮𝐦𝐢𝐧𝐞𝐦.𝐜𝐨𝐦, a leading sustainability information and data platform, and one of Angel List’s ‘𝐓𝐨𝐩 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐒𝐭𝐚𝐫𝐭𝐮𝐩 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞’. In 2024, illuminem achieved "the most participated round by key climate investors worldwide" and "the region's highest valuation for an early-stage climate company". Andrea is also the 𝐲𝐨𝐮𝐧𝐠𝐞𝐬𝐭 𝐩𝐫𝐨𝐟. 𝐚𝐭 𝐇𝐄𝐂 𝐏𝐚𝐫𝐢𝐬 (Europe's #1 business school), where he teaches Europe’s only Greentech course, with the goal of developing the next generation of sustainability leaders. Previous to illuminem, he served as the 𝐁𝐨𝐬𝐭𝐨𝐧 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠 𝐆𝐫𝐨𝐮𝐩’𝐬 (𝐁𝐂𝐆) 𝐆𝐥𝐨𝐛𝐚𝐥 𝐆𝐫𝐞𝐞𝐧 𝐂𝐡𝐚𝐦𝐩𝐢𝐨𝐧, leading projects on sustainable investments and innovation for multinationals & governments. Andrea has been recognized by the 𝐔𝐧𝐢𝐭𝐞𝐝 𝐍𝐚𝐭𝐢𝐨𝐧𝐬 as one of the 50 𝐆𝐥𝐨𝐛𝐚𝐥 '𝐈𝐦𝐩𝐚𝐜𝐭 𝐌𝐚𝐤𝐞𝐫𝐬' ("civil society leaders making the change we need to see"), and by Startup Italia as one of '𝐈𝐭𝐚𝐥𝐲’𝐬 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐨𝐫𝐬'. He is the Sustainability & Innovation 𝐂𝐨𝐥𝐮𝐦𝐧𝐢𝐬𝐭 𝐟𝐨𝐫 𝐀𝐮𝐬𝐭𝐫𝐢𝐚’𝐬 𝐦𝐚𝐢𝐧 𝐧𝐞𝐰𝐬𝐩𝐚𝐩𝐞𝐫, Der Standard; a published author in the Journal of Financial Engineering; and a speaker at events hosted by COP, Davos, and universities around the world. His latest TEDx on ESG has become “the most-watched talk in Italian on sustainability.”

Tatiana Anderson is a tropical plant expert with over 20 years of hands-on experience growing and caring for tropical and subtropical plants. Her work focuses on fruit trees, flowering plants, and climate-sensitive species, with practical guidance based on real growing conditions. She works with a US-based tropical plant nursery that ships plants nationwide and contributes to a large online plant encyclopedia documenting thousands of plant species. Tatiana specializes in plant identification, variety selection, cold protection, and helping gardeners avoid common growing mistakes.

Formerly a business owner in the fashion industry, I have redirected my career to catalyzing positive environmental change. As an Environmental Scientist and Project Manager I am hands on deploying ehnanced phytoremediation systems on contaminated and degraded sites throughout California. As an International Keynote Speaker, I am passionate about raising awareness and inspiring action on pressing environmental issues. Additionally, as a Native Plant Workshop Educator, I empower individuals to connect with their local ecosystems and promote biodiversity starting with their own backyard and communities. Join me in the environmental revolution, and together, we can make a lasting impact on our planet. Let's connect and collaborate for a greener, more sustainable future.

Meet Dhriti Mukherjee Pipil – Trade Economist, Consultant, Speaker & Educator Dhriti Mukherjee Pipil is a Delhi NCR–based international trade economist, consultant, researcher, and speaker, specialising in trade finance, foreign trade policy, and agricultural trade. She is the Founder of Global Trade Institute (GTI), an institution focused on building export-ready professionals and businesses through practical trade education. She currently serves as a Senior Research Fellow at Indian Institute of Foreign Trade (IIFT), where her work examines India’s agricultural trade policy, export restrictions, price volatility, and supply chain dynamics. She is also an empanelled faculty with Federation of Indian Export Organisations (FIEO), delivering specialised sessions on export finance and international payment systems. Dhriti is a Leadership Member at the Women in International Trade Business Council (WIITBC) under the International Trade Council (ITC), and serves on the Economic Advisory Board of the Economic Transformation Council, contributing to trade-led policy discourse. With over a decade of experience in banking and trade finance, her expertise spans export finance, cross-border payments, foreign exchange markets, trade risk management, WTO frameworks, and emerging digital trade finance systems. She holds professional certifications from the Indian Institute of Banking & Finance (IIBF) and the International Chamber of Commerce (ICC). Her work bridges policy, practice, and pedagogy—offering consultancy in export strategy, trade finance structuring, compliance, and market entry. She actively mentors MSMEs and startups, enabling them to navigate global markets with operational clarity. Dhriti has authored peer-reviewed research in journals such as Economic & Political Weekly and The Indian Economic Journal, alongside policy contributions to The Hindu BusinessLine, Down To Earth, Policy Circle, AgroSpectrum, and global platforms including the World Trade Centre. She is a regular speaker at national and international forums, including the Economist Intelligence Unit (2025), International Trade Council (2025), WTO Chairs Programme, and Indian Economic Association. Through her work, she seeks to reduce information asymmetry in global trade and build a more inclusive, resilient, and knowledge-driven export ecosystem.

James Bean is a pioneering cannabis industry expert and Founding CEO of Seeds Here Now, the longest continuously operating seed bank in the United States with 15 years of proven leadership. Since 2010, Bean has built an industry-leading catalog featuring 3,500+ strains from 80+ world-class breeders, establishing Seeds Here Now as the premier destination for authentic cannabis genetics. With a Plant Science degree from Oaksterdam University and 15 years specializing in cannabis genetics, Bean brings unparalleled expertise in breeder verification, genetic authenticity, and cultivation science. His knowledge spans feminized, regular, and autoflower seed production, pheno-hunting, breeding practices, and strain lineage documentation. Bean's industry authority is demonstrated through extensive media presence on major cannabis podcasts including The Adam Dunn Show (as "James Bean Man on the Scene"), The Dude Grows Show, The Pot Cast, and Grow Bud Yourself Podcast. He has personally vended at hundreds of cannabis trade shows including High Times Cannabis Cups and Canna Con events, and serves as a cannabis competition judge. As a heavy cannabis consumer with decades of personal experience, Bean possesses exceptional first-hand knowledge of strain effects and quality assessment. His business has served thousands of satisfied customers with germination guarantees and transparent practices, earning recognition including the 2023 Leafly Seed Bank Hall of Fame honor and Forbes media coverage. Bean actively supports cannabis community causes, mentors emerging businesses, and contributes educational content through articles and podcast appearances. His direct relationships with renowned breeders like TH Seeds, Exotic Genetics, La Plata Labs, Snow High Seeds, and Dominion Seed Company underscore his trusted position as the "#1 U.S. Broker of High Quality Cannabis Genetics." Based in Tulsa, Oklahoma, Bean continues to shape cannabis breeding trends, preserve rare genetics, and advance industry professionalism while maintaining Seeds Here Now's position as America's most trusted source for authentic cannabis seeds.

Emanuele Andreano is an immunologist and biotech innovator redefining how vaccines are discovered for pandemic threats. As Head of Serology and Immunology at the Fondazione Biotecnopolo di Siena and a leader in the European Vaccine Hub, he works at the intersection of AI, immunology, and global health. He pioneered Reverse Vaccinology 3.0, a breakthrough approach that can identify entirely new vaccine targets in days instead of years. In a first-of-its-kind demonstration, his team showed that artificial intelligence can predict unknown viral antigens directly from human antibody sequences—effectively reversing the traditional vaccine discovery process. His work spans monoclonal antibody discovery and next-generation vaccines against emerging pathogens, including mpox and SARS-CoV-2, with direct implications for global pandemic preparedness and biosecurity. Andreano has received international recognition, including the Antonio Feltrinelli Prize from the Accademia Nazionale dei Lincei, awarded in the presence of the President of the Italian Republic Sergio Mattarella, the IUIS Rising Star in Immunology, and a European Research Council (ERC) grant. He also co-directs a vaccinology program at the Institut Pasteur in Paris. “We are entering an era where vaccines can be discovered at unprecedented speed—transforming our ability to fight pandemics and save countless lives.”

Investment industry veteran that cofounded a tech startup to help seniors avoid elder fraud. 30 years experience in the investment and insurance business. Experience over a range of asset classes with deep experience in derivatives and risk management. Early adapter of derivatives in insurance portfolios and mutual funds. Built out independent risk organization at two firms. Experienced Chief Risk Officer(CRO) for US and UCITs funds. Demonstrated commercial instinct. Experience with: Investments Product and Strategy Risk Market Risk and Investment Risk Risk Management of UCITS Derivatives, Futures, Options, Swap Silver tech

Ryan Farmer is the founder of My Peptide Match, a consumer education site that helps people make sense of GLP-1 medications and the fast-changing peptide landscape. He focuses on simplifying complex topics—like real-world pricing, treatment pathways, sourcing differences, and what questions to ask—so readers can make more informed decisions with their clinician. Ryan tracks emerging trends across weight-loss peptides, compounding and telehealth access, and the economics that shape what consumers actually pay. He’s available to comment on GLP-1 and peptide cost comparisons, patient decision-making, and the broader market shifts driving demand. He also publishes practical reference tools, including a peptide calculator and dosage guide, to support clearer conversations between consumers and providers.

Dr. Pouyan Golshani is an interventional radiologist and entrepreneur working at the crossroads of healthcare, technology, and finance. He founded GigHz, the hub where he builds and advises across these domains; RadReport AI, an AI-driven radiology reporting engine that turns dictation into structured, clinically-sound reports; Repit.org, a national real-estate intelligence platform exposing ZIP-level trends, rent trajectories, and investability metrics; and Guide.MD, a physician-first directory designed to fix and control online identity without the usual pain. After nearly two decades in medicine and years of hands-on investing, he’s become a go-to voice for clinicians, founders, and investors who want clear, practical explanations of med-tech innovation, AI in healthcare, real-asset strategy, and tax-efficient decision-making. His work blends clinical judgment with a grounded business lens, giving people accurate, no-nonsense insight without oversimplifying anything. He routinely advises early-stage teams, physicians, and allocators on licensing, diligence, and deal structure — with an emphasis on transparency, strong incentives, and long-term value over hype. The goal is simple: help smart people make better decisions in a system that gets more complex every year.

In my role, I meticulously oversee various clinical projects, ensuring each phase is executed with precision and in compliance with GCP standards. Core Competencies: Clinical Trials Monitoring Clinical Safety Protocols Streamlined Clinical Operations Regulatory Compliance Mastery Educational Background: MSc in Molecular Science and Nanotechnology, Louisiana Tech University MSc in Medical Genetics, MGM University of Health Sciences With a robust educational foundation and a keen eye for detail, I have successfully navigated through different therapeutic areas and regions, delivering high-quality results consistently. My journey in the realm of clinical research is driven by an insatiable curiosity and a deep-seated commitment to advancing science and practice. Let’s Connect! If you are passionate about transforming health care and improving patient lives, or if you wish to exchange insights and collaborate on projects, feel free to connect with me. Together, let’s contribute to a healthier, more understanding world for individuals navigating through challenges.